March 12-15, 2024 | London, UK
Antibody-drug conjugates are the moment right now, with the past year celebrating new approvals, positive clinical data, and over 300 ADCs in various stages of clinical development promising a bright future for these therapies in the fight against cancer.
As the field enters a new era with pipelines continuing to expand for 2024 and beyond, the 14th World ADC London will be your opportunity to reflect on the drivers of success behind the superstar drugs ENHERTU and ELAHARE, discuss exciting novel approaches to drug-conjugate design, finetune translation, understand novel mechanisms of action, combat off-target toxicities and streamline manufacturing processes.
Jia He, our Antibodies and Biologics Manager will be joining the pre-conference speaker faculty to ‘Explore the Rise in ADC Combination Clinical Trials‘, whilst our ADC Insights Lead, Jake Morris, joins the Clinical Lessons track on Day 2 to assess the current state of the ADC landscape. Sharing more data and insights than we have ever before at World ADC, these presentations are not to be missed! You can find out more details online or in the full event guide now.
